News & media
-
Zealand Pharma completes registration of capital increase
-
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion
-
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
-
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
-
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
-
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
-
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
-
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
-
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
-
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
-
Zealand Pharma major shareholder announcement: Polar Capital
-
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
Corporate management
-
Adam Steensberg - President and Chief Executive Officer
-
Adam Steensberg - President and Chief Executive Officer
-
Adam Steensberg - President and Chief Executive Officer
-
Henriette Wennicke - Executive Vice President and Chief Financial Officer
-
Christina Sonnenborg Bredal - Executive Vice President and Chief People Officer
-
David Kendall - Executive Vice President, Research & Development and Chief Medical Officer
-
Ivan Møller - Executive Vice President and Chief Operating Officer
-
Utpal Singh - Executive Vice President and Chief Scientific Officer
-
Utpal Singh - Executive Vice President and Chief Scientific Officer
-
Steven Johnson - Executive Vice President, Chief Development Officer
-
Eric Cox - Executive Vice President, Chief Commercial Officer
Research and development
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
Sustainability
-
Morten Lagstrøm - ESG Officer
Logos and icons
-
)
Zealand Pharma Logo (RGB)
Stay up-to-date with the latest news from Zealand
Sign-up to receive press releases and company announcements directly to your inbox
Investor and Media contacts
